Under this rule, CMS opted for the term SRP as opposed to gender-affirming care because the latter "inaccurately describes ...

Eliot F. Battle, MD, cofounder and CEO of Cultura Dermatology & Laser Center in Washington, DC, and cochair of Skin of Color ...

Despite expanding treatment options for rare glomerular diseases such as immunoglobulin A nephropathy (IgAN) and focal ...

Adults and adolescents with alopecia areata had nearly 8 times higher odds of near-complete scalp hair regrowth on an oral ...

Dr. Haumschild identifies several contributors to SGLT2 inhibitor underuse, starting with fragmentation in care. He says the biggest issue is often the gap between identifying an ...

SGLT2 inhibitors have outgrown their diabetes-only label, and formulary teams that still price them that way are missing the bigger cardiorenal picture entirely.

Follitropin delta (Rekovelle; Ferring), a recombinant follicle-stimulating hormone produced in a human cell line, achieved cumulative ongoing pregnancy rates of 64.0% in patients ...

Although zidesamtinib (Jideytro; GSK) was designed to be better tolerated than other ROS1 inhibitors, it can still cause adverse effects that require monitoring, and questions remain about how best to ...

The Ambulatory Specialty Model (ASM) has the potential to reduce chronic disease costs by holding specialists accountable for ...

Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...